Welcome to our dedicated page for SRX Health Solutions SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions, Inc. has filed a prospectus supplement covering the resale by selling stockholders of up to 187,552,665 shares of common stock. These shares include stock underlying July and October PIPE securities, exchangeable shares, prior private placements, service provider awards, and a share exchange transaction.
Separately, the company redeemed all outstanding Series A preferred stock for an aggregate redemption price of approximately $21,772,500125,000,000 shares of common stock on an as-converted basis, which the company states is intended to improve balance sheet flexibility for potential M&A or returns of capital.
SRx Health Solutions, Inc. is registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners under a common share purchase agreement. The company will not receive proceeds from Keystone’s resales, but can receive cash when it sells shares to Keystone under the equity line.
Separately, SRx Health redeemed 17,418 shares of its Series A Convertible Preferred Stock for an aggregate redemption price of approximately $21,772,500, representing about 125,000,000 common shares on an as-converted basis. The preferred redemption and related common share cancellation are described as improving balance sheet flexibility for potential future M&A or returns of capital.
SRx Health Solutions, Inc. received a major shareholder disclosure from individual investor Kevin Egan. He reports beneficial ownership of 14,031,500 shares of SRx Health common stock, representing 5.0% of the class as of the event date 02/05/2026.
The filing states that Egan has sole power to vote and sole power to dispose of these 14,031,500 shares. He files in his individual capacity, indicates no membership in any group, and reports no ownership on behalf of other persons or subsidiaries.
SRx Health Solutions, Inc. filed a current report describing the full redemption of its Series A Convertible Preferred Stock. The company redeemed all outstanding preferred shares for an aggregate redemption price of approximately $21,772,500 under the terms of its certificate of designations.
According to the accompanying press release, the redeemed Series A Preferred Stock had represented about 125,000,000 shares of common stock on an as-converted basis, which are now canceled. The company previously issued 19,035 preferred shares in a private placement for roughly $15.23 million in proceeds. Management states that eliminating this class of preferred stock and the associated as-converted common shares improves capital structure flexibility for potential future investments or returning capital to shareholders.
SRx Health notes it has no undisclosed immediate plans for mergers and acquisitions as of the release date, but will continue to evaluate opportunities periodically. The company also expects to file its Form 10-Q for the quarter ended December 31, 2025 on February 13, 2026.
SRx Health Solutions, Inc. reports that NYSE American has accepted its plan to regain compliance with listing standards, allowing its common stock to continue trading during a plan period ending July 14, 2026. The company must give NYSE American quarterly updates on its progress toward the plan’s goals.
NYSE American previously notified the company that it fell below the continued listing requirement for stockholders’ equity of $4 million after SRx Health Solutions reported stockholders’ equity of ($45.9) million as of June 30, 2025, along with losses in three of its four most recent fiscal years ended December 31, 2024. The company states that it intends to regain compliance with Section 1003(a)(i) within the plan period.
SRx Health Solutions, Inc. filed a prospectus supplement covering the resale of up to 187,552,665 shares of common stock held by selling stockholders. These shares come from prior PIPE financings in July and October 2025, exchangeable shares issued in connection with SRx Health Solutions (Canada), a private placement, service provider share issuances, and shares issued under a share exchange with Halo Spin-Out SPV Inc.
The supplement includes a Current Report on Form 8-K describing stockholder written consents dated December 17, 2025. Stockholders approved a future name and ticker change to EMJX, a potential issuance of at least 20% of outstanding common stock for a transaction to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp. and related AI-based intellectual property, an increase in the 2019 Incentive Award Plan share pool, the election of four directors, advisory approval of executive compensation, and ratification of Davidson and Company LLP as auditor. These actions were approved by holders of 45.42% of the company’s voting power as of the December 12, 2025 record date.
SRx Health Solutions, Inc. is registering up to 187,544,974 shares of common stock for resale by existing holders, including shares issuable from PIPE financings, exchangeable shares, private placements, service provider grants and a prior share exchange. The company will not receive proceeds from these resales, which could put pressure on the share price because the registered amount represents a meaningful portion of its public float.
The prospectus describes significant financing arrangements, including July and October PIPE deals, an equity line of credit that may allow sales of up to $1.0 billion of common shares, and a $20.0 million convertible note tied to that facility. It also highlights serious risks: the auditors have raised substantial doubt about the company’s ability to continue as a going concern, the Canadian subsidiary SRx Canada is in CCAA restructuring with asset sales under court supervision, and the Halo pet business has recurring losses and intense competitive and operational pressures.
SRx Health Solutions, Inc. filed a prospectus supplement covering the resale of up to 2,506,893,959 shares of common stock by Keystone Capital Partners, LLC. These shares are outstanding or issuable under a common share purchase agreement, and any sale by Keystone will not send cash to the company, although SRx would receive funds when it sells shares to Keystone under that agreement.
Separately, stockholders holding 45.42% of voting power approved several actions by written consent as of December 17, 2025. These include a planned name change to EMJX, Inc. and ticker change to EMJX conditioned on closing a proposed transaction to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp., and related artificial intelligence trading intellectual property. Stockholders also approved potential issuance of common stock equal to 20% or more of current outstanding shares in connection with this transaction, an increase in the 2019 Incentive Award Plan pool, election of four directors to terms through the 2026 annual meeting, advisory approval of executive compensation, and ratification of Davidson and Company LLP as independent auditor for 2025.
SRx Health Solutions, Inc. reported that stockholders holding 12,591,645 votes, or 45.42% of outstanding voting power on an as-converted basis as of the December 12, 2025 record date, approved several actions by written consent. This exceeded the one-third threshold required under Delaware law and the company’s bylaws, so no meeting was held.
Stockholders approved changing the company’s name to EMJX, Inc. and its NYSE American ticker from SRXH to EMJX, conditioned on closing a proposed transaction with EMJ Crypto Technologies Inc., CCC Crypto Corp., and other transferors. They also approved issuing shares of common stock that may equal 20% or more of current outstanding common stock, potentially at below-market value, to acquire those entities and associated artificial intelligence-driven crypto trading intellectual property, and to appoint Eric M. Jackson, PhD as CEO and board chair in connection with the transaction.
Additional approvals included increasing the 2019 Incentive Award Plan pool to 10% of shares outstanding, but not less than 3,432,915 shares, electing four directors to terms running to the 2026 annual meeting, a non-binding advisory vote on executive compensation, and ratifying Davidson and Company LLP as auditor for 2025. Before closing the transaction or implementing these actions, the company will file and mail a Schedule 14C information statement.
SRx Health Solutions, Inc. is registering up to 187,544,974 shares of common stock for resale by existing selling stockholders. These shares come primarily from recent financings, including July and October PIPE transactions, an April 2025 private placement, shares issued to service providers, exchangeable shares tied to SRx Health Solutions (Canada), Inc., and a share exchange with Halo Spin-Out SPV Inc. The company will not receive proceeds from these resales.
As of December 19, 2025, SRx had 69,555,603 common shares outstanding, and the registered resale shares represent about 7% of its fully diluted share count. The prospectus highlights substantial financing activity, including secured convertible notes, preferred stock with attached warrants, and a $1.0 billion equity line of credit, alongside a going concern warning and a stated need for additional capital. SRx’s operating focus centers on its Halo pet health and wellness brand, while its Canadian affiliate is in CCAA restructuring. The company has also agreed to a proposed all-stock acquisition of EMJ Crypto Technologies Inc. and related assets valued at approximately $55 million, subject to shareholder and regulatory approvals.